Company Number: 12948837

Analysis Date: 2025-07-20 11:17 UTC

Financial Health Assessment for SENISCA LTD (as of 31 December 2023)

---

1. Financial Health Score: B-

Explanation:
SENISCA LTD shows solid foundational strength with positive net assets and a strong equity base, but some symptoms indicate stress in liquidity and working capital management compared to previous years. The company is investing heavily in fixed assets, which is positive for growth but has reduced current asset buffers and increased liabilities. The recent capital injection post year-end is a positive sign for financial stamina.

---

2. Key Vital Signs

Metric	2023 Value	Interpretation
Fixed Assets	£327,046	Increased significantly, showing investment in growth assets.
Current Assets	£786,649	Decreased from prior years, indicating tighter liquidity.
Cash at Bank	£353,555	Reduced substantially from £1.59M in 2022, a concern for cash flow health.
Debtors	£433,094	Slight decline, but still a significant amount tied up in receivables.
Current Liabilities	£318,554	Increased over 4x from previous year, raising short-term obligations.
Net Current Assets	£468,095	Positive but sharply down from £1.99M, showing reduced working capital.
Net Assets	£716,399	Down from £2.1M, due to reduced current assets and increased liabilities.
Shareholders' Funds	£3,450,044	Very strong equity base, reflecting prior capital contributions.
Profit & Loss Reserves	Negative £2,733,818	Accumulated losses impacting retained earnings—typical for R&D intensive firms.

---

3. Symptoms Analysis

• Liquidity “Pulse” Weakening:
  The company’s cash reserves have shrunk drastically in 2023 compared to 2022, from over £1.5 million to just £353k. This is a symptom of cash burn or increased spending, possibly linked to expansion or R&D. While current assets remain positive, the significant rise in current liabilities (from £70k to £318k) signals increased short-term debt pressure.

• Working Capital “Balance” Decline:
  The net current assets dropped by over 75% year-on-year, a sign that short-term assets are less able to cover immediate obligations. This could cause operational strain if not managed carefully, especially if debtors take longer to pay.

• Investment in Fixed Assets (“Growth Stimulus”):
  Fixed assets nearly tripled, driven by large additions in laboratory equipment and intangible assets (e.g., patents/licenses). This indicates active scaling or product development, which is a positive sign for future revenue generation but requires healthy cash flow to sustain.

• Equity Base Stability (“Capital Backbone”):
  Shareholders' funds remain robust at £3.45M, unchanged from prior years, showing strong initial funding and capital support. However, accumulated losses have increased, eroding retained earnings and net assets.

• Post-Year Capital Injection (“Rescue Dose”):
  Early 2024 saw a significant external investment of £3.7M, an encouraging sign that investors have confidence and have provided a financial lifeline to strengthen liquidity and fund growth.

---

4. Diagnosis

SENISCA LTD is currently in a growth phase, investing heavily in assets and expanding its operational base, which is putting pressure on liquidity and working capital. The company exhibits symptoms typical of an early-stage biotech R&D firm: significant accumulated losses, tight cash flow, but strong backing from shareholders and fresh capital injections.

The financial health is fair but fragile. While the company’s balance sheet shows strong equity, the strain on current assets relative to liabilities and reduced cash reserves reveal a “financial pulse” that requires careful monitoring. Without ongoing funding or improved cash inflows, there could be risks of short-term distress.

---

5. Recommendations

• Enhance Cash Flow Management:
  Prioritise accelerating debtor collections and closely monitor cash burn rates. Implement tighter credit controls if possible.

• Manage Current Liabilities:
  Negotiate longer payment terms where feasible to ease short-term pressure. Avoid excessive new short-term borrowing.

• Leverage Recent Capital Injection:
  Use the £3.7M fresh equity to strengthen working capital and support R&D without over-relying on debt. Maintain transparency with investors on financial progress.

• Focus on R&D ROI:
  Ensure investments in fixed assets and intangible assets translate into commercialisable products or partnerships to generate revenue in the medium term.

• Regular Financial Health Checks:
  Conduct quarterly reviews of liquidity ratios and cash flow forecasts to detect early signs of distress and adjust plans accordingly.

• Consider Contingency Planning:
  Prepare for alternative financing routes or cost adjustments to maintain a “healthy financial heartbeat” during growth phases.

---

Explanation of Technical Terms (For Clarity)

• Fixed Assets: Long-term resources like lab equipment that support business operations and growth.
• Current Assets: Short-term resources (cash, receivables) expected to be converted to cash within a year.
• Current Liabilities: Debts and obligations due within a year.
• Net Current Assets: The “working capital,” or the cushion available after covering short-term debts.
• Shareholders’ Funds: The money invested by owners plus accumulated profits or losses.
• Profit & Loss Reserves: The cumulative earnings retained in the business after dividends and losses.

---